The Use of Artificial Intelligence to Accelerate Genomic Variant Interpretation

Advancements in artificial intelligence (AI) are reshaping numerous scientific and clinical domains, with genomics emerging as one of the most active frontiers. Among the most promising and immediately impactful applications is the interpretation of genomic variants — alterations in DNA sequences that can range from benign polymorphisms to highly pathogenic mutations that drive disease. As the cost of whole-genome and whole-exome sequencing continues to drop, the volume of data requiring analysis has exploded. However, the bottleneck has shifted from raw sequencing to the accurate and timely interpretation of the millions of variants each genome harbors. AI, particularly machine learning and deep learning, offers a powerful toolkit to accelerate this interpretation, improve consistency, and ultimately deliver precision medicine at scale.

Genomic variant interpretation is the process of determining whether a specific genetic change is likely to contribute to a patient’s phenotype or disease risk. It is a complex, multi-step task that integrates population frequency data, functional annotations, evolutionary conservation scores, known disease associations, and increasingly, predictions from computational models. Historically, this has been a labor-intensive process requiring expert clinical geneticists, and it remains a major rate-limiting step in diagnostic genomics. AI methods can process vast datasets in minutes, identify subtle patterns invisible to human experts, and provide probabilistic scores that guide prioritization. This article explores how AI is being deployed to accelerate variant interpretation, the technologies driving these advances, the challenges that remain, and the future directions that promise to further transform clinical genomics.

The Importance of Genomic Variant Interpretation

From Sequencing to Clinical Action

The primary goal of genomic medicine is to link genetic variation to human health. When a patient presents with symptoms suggestive of a genetic disorder, sequencing their genome or exome can reveal thousands of coding variants and tens of thousands of non-coding variants. The critical task is to identify which of these variants are causative. Missed or misinterpreted variants can lead to incorrect diagnoses, unnecessary treatments, or missed opportunities for preventive care. The stakes are high, and the process must be both accurate and efficient.

Interpretation typically follows established guidelines, such as those from the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP), which classify variants into five categories: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign. Classifying a variant as pathogenic often requires multiple lines of evidence: it must not be common in population databases like gnomAD, it should alter a protein in a way predicted to be damaging, it should segregate with disease in families, and functional studies should support a deleterious effect. Gathering and weighing this evidence is time-consuming and subject to inter-operator variability.

The Bottleneck of Variant Interpretation

The scale of the problem is immense. A typical exome reveals about 20,000 to 30,000 variants, of which only a handful are likely to be disease-relevant. Laboratories performing clinical sequencing can generate tens of thousands of new variants per month. Manual review of all borderline candidates is impractical. Moreover, reanalysis of previously uncertain variants as new knowledge emerges is a recurring task that further strains resources. AI-driven tools offer a path to automate and standardize many aspects of interpretation, from initial filtering to final classification.

The Role of Artificial Intelligence

Artificial intelligence, especially machine learning and deep learning, has demonstrated remarkable ability to learn complex patterns from large datasets. In genomics, AI models are trained on curated sets of known pathogenic and benign variants, along with a wealth of genomic features — conservation scores, epigenetic marks, protein structure data, functional annotation, and more. Once trained, these models can predict the likelihood that a novel variant is deleterious. This capability significantly accelerates the interpretation process by providing a pre-screened list of high-priority variants that can then be evaluated manually with greater focus.

Machine Learning Techniques in Practice

Several families of algorithms are used for variant effect prediction. Supervised learning models such as random forests, support vector machines, and gradient boosting machines have been used in tools like CADD (Combined Annotation-Dependent Depletion), which integrates multiple annotations into a single score. Deep learning models, particularly convolutional neural networks (CNNs) and recurrent neural networks (RNNs), can process raw sequence data or structural information. For example, SpliceAI uses a deep neural network to predict splicing alterations from DNA sequence alone, achieving high accuracy. PrimateAI leverages deep learning on data from primate species to identify variants under negative selection.

Another important approach is unsupervised learning. Models like Eigen and GERP++ primarily use evolutionary conservation without relying on labeled pathogenic variants, making them valuable when training data is sparse. Transfer learning is also gaining traction, where a model pre-trained on a large genomic corpus is fine-tuned for specific tasks, such as clinical variant classification. This approach can improve performance in rare diseases where labeled variants are limited.

Natural Language Processing for Genomic Reports

AI is not limited to variant effect prediction. Natural language processing (NLP) models are being developed to extract evidence from scientific literature and clinical databases automatically. Tools like PubTator and BioBERT can parse millions of abstracts to find gene-disease associations, functional studies, or population data that may influence interpretation. Integrating NLP outputs into the classification pipeline reduces the manual literature review burden and ensures that up-to-date evidence is considered.

How AI Improves Accuracy in Variant Interpretation

Training on Curated Gold Standards

The accuracy of AI models depends critically on the quality and diversity of training data. Curated databases such as ClinVar provide thousands of expert-reviewed variant classifications. However, these datasets can have biases — for example, overrepresentation of well-studied genes and underrepresentation of benign variants. To mitigate this, researchers use negative selection signals from large population cohorts, assume most rare missense variants are neutral, and incorporate functional screening data from multiplex assays of variant effect (MAVEs). Models that are trained on both clinical and population-scale data achieve better generalizability. For instance, the REVEL ensemble model combines scores from multiple predictors and has shown strong performance in identifying pathogenic missense variants.

Integrating Multimodal Data

One of the most exciting developments is the integration of diverse data types into unified prediction frameworks. Modern AI models can simultaneously process nucleotide sequences, protein structures, epigenetic marks, and even 3D genome architecture. AlphaFold and related structural models provide protein folding predictions that can be used to assess whether a variant destabilizes a critical domain. Enformer is a deep learning model that predicts gene expression from DNA sequence alone, enabling assessment of non-coding variants that affect regulatory regions. By combining these diverse signals, AI can capture a more comprehensive picture of variant impact.

Reducing Human Subjectivity

Manual variant interpretation is inherently subjective. Two different geneticists may assign different classifications to the same variant, especially when evidence is conflicting or incomplete. AI models provide a consistent, reproducible score for every variant, reducing inter-rater variability. This standardization is particularly valuable for large-scale sequencing projects and for laboratories seeking to maintain consistent diagnostic practices. However, it is important to note that AI scores are probabilistic and should be used as evidence, not as definitive classifications.

Automation and Efficiency in Clinical Workflows

High-Throughput Variant Filtering

In a clinical laboratory, the first step after sequencing is often to filter out common polymorphisms using population allele frequency thresholds. AI-based scores can be used to rank remaining variants by predicted pathogenicity, allowing analysts to focus on the top 1–2% of candidate variants. Tools like VEP (Variant Effect Predictor) and CADD are widely used to generate precomputed scores that integrate seamlessly into existing pipelines. Some AI models can also predict the clinical actionability of a variant — for example, whether it is likely to cause a severe early-onset disease or a mild adult-onset condition.

Reanalysis and Evolving Knowledge

Many variants initially classified as VUS are reclassified over time as new evidence emerges. Reanalysis of all previously interpreted variants manually is impractical. AI-driven reanalysis platforms can automatically scan updated databases and knowledge bases, applying current prediction models to variant sets. This can lead to a significant increase in diagnostic yield. For example, studies have shown that reanalyzing exome data with updated AI tools can result in a 10–15% increase in molecular diagnoses. Some clinical services are now offering periodic AI-driven reanalysis as a routine service, ensuring that patients benefit from the latest computational advances.

Integration with Electronic Health Records

To accelerate clinical interpretation, AI models can be linked to electronic health records (EHRs). By extracting patient phenotypes, family history, and treatment outcomes, these models can provide context-specific predictions. For example, a variant in a gene associated with cardiomyopathy might be interpreted differently if the patient has a history of heart failure. DeepPheno and similar tools use NLP to extract structured phenotypes from clinical notes, which can then be combined with variant effect scores to rank candidates. This integration reduces the manual effort of chart review and helps prioritize variants that align with the patient’s actual presentation.

Challenges and Limitations of AI in Variant Interpretation

Data Quality and Representativeness

AI models are only as good as the data on which they are trained. Many training sets suffer from ascertainment bias: they overrepresent known disease-causing variants in well-studied genes and ethnic populations. Variants from underrepresented populations are less likely to be correctly classified, which can exacerbate health disparities. Efforts like the All of Us Research Program and gnomAD are making strides to increase diversity, but much work remains. Additionally, training data often contain misclassified variants, which can mislead the model. Robust quality control and regular updating of training sets are essential.

Interpretability and the Black Box Problem

Many deep learning models are considered “black boxes” because they do not provide intuitive explanations for their predictions. In a clinical setting, geneticists need to understand why a model flagged a variant as pathogenic — which features drove the decision — before they can trust and incorporate that evidence. Model interpretability techniques, such as SHAP (SHapley Additive exPlanations) and saliency maps, are actively being developed to highlight the most important input features. However, these methods are still evolving and may not fully satisfy regulatory requirements for explainability. Some regulatory bodies, such as the FDA, are developing frameworks for evaluating AI-based medical devices, including requirements for transparency and validation.

Overreliance and the Need for Expert Oversight

AI tools can be remarkably accurate, but they are not infallible. Overreliance on AI scores could lead to missed diagnoses if the model fails to recognize a rare or atypical variant pattern. It is critical that AI predictions are treated as one line of evidence among many, and that final classification decisions remain in the hands of qualified clinical geneticists. Laboratories should establish guidelines for how AI scores are incorporated into the evidence framework, and should regularly audit model performance against new ground-truth data. In some contexts, AI is used as a triage tool to filter out clearly benign variants, while suspicious variants are still reviewed manually.

Data Privacy and Ethical Considerations

Training AI models on genomic data raises significant privacy concerns. Genomic data is inherently identifiable, and sharing it for model development requires careful consent and de-identification. Federated learning, where models are trained across multiple institutions without sharing raw data, is a promising approach to preserve privacy while leveraging larger datasets. Ethical considerations also include the potential for AI to be used in ways that reinforce existing biases or lead to discrimination. Robust governance frameworks and adherence to principles of fairness, accountability, and transparency are necessary to ensure that AI applications in genomics serve all populations equitably.

Multimodal and Foundation Models in Genomics

The next generation of AI tools will likely be built on foundation models — large, pre-trained models that can be fine-tuned for a wide range of tasks. DNABERT and Nucleotide Transformer are examples of models that have been pre-trained on whole genome sequences and can be adapted for variant effect prediction, regulatory element identification, and even generation of synthetic sequences. These models learn the “language” of DNA and can capture long-range interactions that are missed by traditional methods. When combined with protein language models like ESM-1b, they offer a unified view of how genetic variation propagates from DNA to protein to phenotype.

Integration with Real-World Evidence

AI models are increasingly being trained on real-world clinical outcomes, such as from longitudinal patient registries, clinical trials, and EHRs. This allows predictions to be calibrated to actual disease manifestations, not just computational scores. PheWAS (Phenome-Wide Association Studies) coupled with AI can identify variant-phenotype associations at scale. For example, a model might predict that a specific variant in TTN increases the risk of atrial fibrillation, and this prediction can be validated against a large EHR-linked biobank. Such approaches will drive the transition from variant interpretation based solely on molecular prediction to interpretation grounded in real-world evidence.

Real-Time Clinical Decision Support

As computational power grows and AI models become more efficient, it will be possible to run variant interpretation in real time during a clinical encounter. Imagine a geneticist reviewing a variant in a patient’s record and instantly receiving an AI-generated summary of all relevant evidence, including population frequencies, functional predictions, literature associations, and drug implications. This would dramatically reduce the turnaround time for diagnostic reporting and could enable near-instantaneous results for acute care settings, such as neonatal intensive care units where genetic syndromes must be diagnosed within days.

Regulatory and Clinical Adoption

For AI to be widely adopted in clinical variant interpretation, clear regulatory pathways must be established. The FDA has already authorized several AI-based software tools for medical imaging, and similar frameworks are being developed for genomics. Validation studies using large, prospective cohorts are essential. Companies like Fabric Genomics and Illumina are already commercializing AI-driven interpretation platforms that have been tested in clinical settings. As more evidence accumulates, we can expect professional societies to issue guidelines on the appropriate use of AI in diagnostic genomics, similar to current ACMG/AMP criteria but with provisions for computational evidence.

Conclusion

The integration of artificial intelligence into genomic variant interpretation represents one of the most impactful convergences of computational science and medicine. By leveraging machine learning and deep learning on ever-growing datasets, AI tools can prioritize variants, predict functional effects, and even suggest clinical classifications with speed and consistency unmatched by manual methods. This acceleration is not merely a convenience — it is a necessity as genomic sequencing becomes a routine part of healthcare. While challenges around data quality, interpretability, and bias remain, active research and thoughtful regulation are paving the way for responsible adoption. As AI models become more sophisticated, multimodal, and integrated with real-world outcomes, they will play an increasingly central role in translating a patient’s genome into actionable clinical insights. The ultimate beneficiaries are patients, who will receive faster diagnoses, more personalized treatments, and improved health outcomes through the power of intelligent tools that amplify — rather than replace — the expertise of clinicians and geneticists.